The impact of rosiglitazone on heat tolerance in patients with type 2 diabetes.

Background: Diabetes is associated with reduced tolerance to heat. The insulin sensitizer rosiglitazone (RSG), administered for glycemic control, has a secondary effect in increasing vascular endothelial function. The hypothesis to be tested was if administration of rosiglitazone would increase heat tolerance in people with diabetes.

Effects of electrical stimulation on skin blood flow in controls and in and around stage III and IV wounds in hairy and non hairy skin.

Background: While wounds heal more quickly when electrical stimulation (ES) is applied, few studies have examined blood flow (BF) in and around wounds during ES in controls with no wounds compared to wounds in diabetic and non diabetic subjects.

Material/methods: Ten subjects with stage III and IV wounds and 8 controls were subjected to 5 minutes of biphasic ES (20 milliamps, pulse width 250 usec). Before, during, and after, BF were measured by a Laser Doppler Imager.

Gait characteristics in patients with type 2 diabetes; improvement after administration of rosiglitazone.

Background: Gait is impaired in people with type 2 diabetes. An insulin sensitizer, rosiglitazone(RSG) has promise to reverse some of the circulatory impairments seen in diabetes. The hypothesis to be tested was if RSG would improve gait in patients with diabetes.